KARACHI: A medicine is not an ordinary product. A patient prescribed a course of treatment cannot easily postpone it, substitute it, or shop around the way they would for a shirt — and that simple fact shapes everything about Pakistan's listed pharmaceutical companies: how their products are priced, who regulates them, why their earnings have historically been steadier than most manufacturers', and why a long-running argument about deregulating drug prices matters so much to their future. On the Pakistan Stock Exchange, pharmaceutical shares are often described as defensive — businesses whose demand holds up when the economy weakens. That description is broadly fair, but incomplete. Behind the steady demand sits a regulatory system in which the state has historically set maximum prices for most medicines, imported raw materials are paid for in dollars, and a single policy decision can redraw the sector's margins. This guide explains how pharma companies in Pakistan make money, how the Drug Regulatory Authority of Pakistan (DRAP) pricing system works, what the deregulation debate is actually about, and how to read a pharma company's results with clear eyes.
How a pharmaceutical company makes money
A listed drug maker earns revenue by manufacturing and selling medicines — tablets, capsules, syrups, injectables, creams and more — under brand names that doctors prescribe and pharmacists dispense. Most large Pakistani producers combine several kinds of business. They manufacture their own branded generic products: medicines whose original patents have expired, sold under the company's own brand and promoted to doctors. Some operate under licence from multinational research companies, making and marketing those firms' products locally; a few listed companies are themselves subsidiaries of global groups. Many also earn from contract manufacturing, nutritional products, and exports to markets in Asia, Africa and beyond, where Pakistani-made medicines compete on price and quality.
The value chain runs from active pharmaceutical ingredients (APIs) — the chemicals that actually treat the condition — through formulation, packaging, quality testing, and a distribution network that reaches pharmacies in every city and town. Pakistan imports the large majority of its APIs and many other raw materials, principally priced in foreign currency, while selling the finished medicine in rupees at regulated prices. That mismatch — dollar costs, rupee prices, and a regulator between the company and any price increase — is the sector's defining economic tension. Costs include far more than ingredients: maintaining good-manufacturing-practice (GMP) plants, laboratories, a large medical sales force that visits doctors, and distribution margins for wholesalers and pharmacies all sit between the factory gate and the patient. When you see a pharma company's gross margin, you are seeing what remains after manufacturing costs; the selling and medical-promotion expenses below it are substantial and are part of how brands are built in a market where the prescriber, not the patient, usually chooses the product.
DRAP and the pricing system
The Drug Regulatory Authority of Pakistan, established under federal law, registers medicines, licenses manufacturing sites, inspects quality, and — working within the federal government's drug pricing policy — sets maximum retail prices for medicines sold in Pakistan. Historically, the system worked roughly as follows: a company applied for a price when registering a product; increases on existing products were governed by formulas linked, in various periods, to inflation measures, with different treatment for so-called essential and non-essential medicines; and companies facing exceptional cost pressure on particular products could apply for hardship increases, submitting cost evidence for specific drugs whose regulated price had fallen below the cost of making them. The precise formulas and categories have changed over time and continue to evolve — this is an area where any specific detail should be checked against current DRAP and federal government notifications, not taken from any article, including this one.
Two consequences follow for investors. First, pricing power is limited and lumpy: a company cannot simply raise prices when its rupee costs jump after a currency depreciation; it must wait for policy adjustments, formula-based increases or case-by-case approvals, and in the interval its margins absorb the shock. Second, volume becomes the reliable growth engine. Companies grow by launching new molecules as patents expire globally, expanding into therapeutic areas such as cardiology, diabetes and mental health where chronic treatment creates repeat demand, winning share through brand trust among doctors, and exporting. Chronic-therapy products deserve a note: a patient on a long-term prescription refills month after month, which is why portfolios weighted toward chronic care tend to produce smoother revenue than portfolios dependent on seasonal antibiotics and acute treatments. The regulatory interplay here is quite different from fertilizer, where the administered price is on the input; in pharma, the administered price is on the output — and that difference explains much of each sector's character.
The deregulation debate
In recent years, Pakistan has debated — and begun moving toward — deregulating the prices of medicines classified as non-essential, while keeping controls on the essential medicines list. The arguments deserve a fair hearing on both sides, because investors who understand only one side will misread the policy risk. The industry case runs like this: decades of tight control, punctuated by rupee depreciations that raised imported-input costs, squeezed margins until some products became uneconomic to produce, contributing to periodic shortages of certain medicines; allowing market pricing on non-essential products would restore incentives to manufacture, invest in quality and launch new products, and competition among many branded generics would restrain prices in practice. The cautionary case runs like this: medicines are not ordinary goods, patients cannot judge quality or defer treatment, information is unequal, and deregulation risks sharp price rises for products with few substitutes, hitting households for whom health spending is already a major burden; regulators in comparable countries therefore keep some form of oversight even in liberalised systems.
What matters for a PSX investor is the direction, pace and design of reform rather than slogans. Which products are classified as essential? How are increases on still-regulated products calculated? How quickly are decisions implemented, and do they survive changes of government? Each choice moves expected earnings for the whole sector at once — this is systemic policy exposure, similar in kind to the gas-price exposure of fertilizer makers and quite unlike company-specific risks such as a single factory problem. Company disclosures and DRAP notifications are the primary sources; treat confident predictions from any commentator, bullish or bearish, as opinion. Our guide to researching a listed company explains how to find and read those primary disclosures on the PSX feed.
Costs: dollars in, rupees out
Return to the cost side, because it explains most quarterly surprises. When the rupee depreciates, the cost of imported APIs, packaging materials and machinery rises almost immediately, while regulated selling prices adjust slowly or not at all — margins compress. When the rupee stabilises and formula-based price adjustments come through, margins recover — sometimes sharply, which can make a recovery year look like a breakthrough. Energy costs matter too, since sterile manufacturing, air-conditioning of clean areas and cold chains for temperature-sensitive products are power-hungry. Finance costs rise and fall with the State Bank's policy rate, as in every sector, though pharma companies have historically carried less debt than heavy industry.
An illustrative example makes the squeeze concrete. Suppose — purely for illustration — a medicine sells at a regulated maximum of Rs 500 per pack, and its imported ingredients cost the equivalent of Rs 200 when the exchange rate sat at one level. If the rupee weakens by a quarter against the dollar, the same ingredients may cost roughly Rs 250, while the selling price remains Rs 500 until an adjustment is approved. Fifty rupees of margin per pack has vanished without the company selling one pack fewer or running its plant any worse. Scale that across millions of packs and you have the sector's typical difficult year — and, in reverse, its typical recovery. This is why experienced readers of pharma results always ask two questions before celebrating or panicking: what did the currency do, and what pricing relief arrived during the period?
Quality, trust and the moat question
Medicines are trust goods: neither patient nor, often, doctor can directly verify what is in a tablet, so brands, manufacturing reputation and regulatory standing carry unusual weight. A company with a record of quality — clean inspections, reliable supply, well-known brands — can hold share against cheaper rivals in a way that a commodity producer cannot. The dark side of the same coin is that quality failures, product recalls or regulatory action carry outsized reputational and financial cost, and the sector worldwide lives under continuous inspection regimes for exactly this reason. Investors should also understand the informal context: Pakistan's medicine market includes a large number of registered products and brands competing in the same molecule, which limits any single brand's pricing freedom even where prices are deregulated — competition, not only regulation, disciplines this market.
Exports are the sector's long-term option. Pakistani manufacturers supply a range of developing markets, and registration of products in each export destination takes time and investment in plant standards. Export revenue has a natural hedge quality — it is earned in foreign currency against partly local costs — but building it is slow, regulated market by market, and rarely transforms a company in a single year. When a company's commentary highlights export growth, check whether it is growth from a small base and whether margins on exports are disclosed; enthusiasm should be proportional to evidence.
Reading results and the risks that remain
A structured read of a pharma result starts with revenue growth split, where disclosed, between price and volume — volume-led growth in a controlled-price regime usually signals genuine franchise strength. Then gross margin, interpreted against currency movement and pricing decisions in the period. Then selling expenses: a rising medical-promotion bill is normal in launch years but should eventually be justified by the sales it builds. Note new product launches and their therapeutic areas; note one-off items such as exchange losses, which can distort a quarter; and check operating cash flow against profit, since receivables from distributors and hospitals can absorb cash in a growing business.
The standing risks are the mirror of the sector's strengths. Regulatory risk on pricing is permanent, whichever direction policy moves. Currency risk is structural while APIs are imported. Quality and compliance risk is low-frequency but severe. And valuation risk — the risk that steady businesses get priced for perfection — applies here as everywhere: a defensive company bought at any price is no longer a defensive investment. This article is educational content, not financial advice. Pharma rewards the same discipline as the neighbouring sectors in this series: in automobiles, demand swings with the cycle; in pharma, demand endures, and it is the price — set in an office in Islamabad as much as in the market — that does the swinging.
Multinationals, local champions and generics
One more structural distinction helps make sense of the listed sector. Some PSX pharmaceutical companies are subsidiaries of global groups, manufacturing and marketing their parents' researched brands alongside local products; they benefit from pipelines of new molecules and global quality systems, and they pay royalties and dividends to their parents. Others are Pakistani-owned companies that built portfolios of branded generics and, increasingly, their own presence in export markets and adjacent health businesses such as nutritionals, consumer health and medical devices. Both models can be sound; they differ in where new products come from, who controls strategy, and how much of the profit stays in the listed company for local shareholders. A third pattern is the pure generics manufacturer competing mainly on cost and distribution reach. When comparing companies, identify the model first, then judge execution within it — comparing a research-brand subsidiary's margins with a generics maker's margins, without that context, compares different businesses wearing the same sector label. Portfolio breadth matters too: a company dependent on a handful of top-selling brands carries concentration risk if any one brand faces new competition, a regulatory question or a supply problem with a single imported ingredient, whereas a broad portfolio of mid-sized brands is duller and sturdier. Annual reports list leading brands and therapeutic segments; that page, unglamorous as it looks, is one of the most informative in the whole report, because it shows you exactly which prescriptions the company's profits depend on, season by season and doctor by doctor.
Key takeaway: pharma on the PSX pairs steady, need-based demand with regulated prices and dollar-linked costs — margins live in the gap between DRAP decisions and the exchange rate, so read volume growth, pricing relief and currency together.
